Background/Aims: By the release of antiangiogenic factors, Müller glial cells provide an angiostatic environment in the normal and ischemic retina. We determined whether Müller cells produce thrombospondin-1 (TSP-1), a known inhibitor of angiogenesis. Methods: Secretion of TSP-1 by cultured Müller cells was determined with ELISA. Slices of rat retinas and surgically excised retinal membranes of human subjects were immunostained against TSP-1 and the glial marker vimentin. The effects of TSP-1 on the growth of bovine retinal endothelial cells (BRECs) and activation of ERK1/2 were determined with DNA synthesis and migration assays, and Western blotting, respectively. Results: Cultured Müller cells secrete TSP-1 under normoxic and hypoxic (0.2% O2) conditions. Secretion of TSP-1 was increased in hypoxia compared to normoxia. In rat retinal slices, glial, retinal ganglion, and possibly horizontal cells were stained for TSP-1. Retinal glial cells in preretinal membranes from human subjects with nonhypoxic epiretinal gliosis (macular pucker) and proliferative diabetic retinopathy, respectively, were immunopositive for TSP-1. Exogenous TSP-1 reduced the VEGF-induced proliferation and migration of BRECs and decreased the phosphorylation level of ERK1/2 in BRECs. Conclusion: The data suggest that Müller cells are one major source of TSP-1 in the normal and ischemic retina. Glia-derived TSP1 may inhibit angiogenic responses in the ischemic retina.

Keywords:
Thrombospondin, Ischemia, Angiogenesis, Diabetic retinopathy, Glia, Vascular endothelium, Retina
1.
Klein BE: Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol 2007;14:179-183.
2.
Cheung N, Mitchell P, Wong TY: Diabetic retinopathy. Lancet 2010;376:124-136.
3.
Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO: Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003;22:1-29.
4.
Simó R, Carrasco E, García-Ramírez M, Hernández C: Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diabetes Rev 2006;2:71-98.
5.
Duh EJ, Yang HS, Haller JA, et al: Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor: implications for ocular angiogenesis. Am J Ophthalmol 2004;137:668-674.
6.
Eichler W, Yafai Y, Wiedemann P, Fengler D: Antineovascular agents in the treatment of eye diseases. Curr Pharm Des 2006;12:2645-2660.
7.
Rivera JC, Aranda J, Riesgo J, et al: Expression and cellular localization of prolactin and the prolactin receptor in mammalian retina. Exp Eye Res 2008;86:314-321.
8.
Amin RH, Frank RN, Kennedy A, Eliott D, Puklin JE, Abrams GW: Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 1997;38:36-47.
9.
Abu El-Asrar AM, Meersschaert A, Dralands L, Missotten L, Geboes K: Inducible nitric oxide synthase and vascular endothelial growth factor are colocalized in the retinas of human subjects with diabetes. Eye 2004;18:306-313.
10.
Eichler W, Yafai Y, Keller T, Wiedemann P, Reichenbach A: PEDF derived from glial Müller cells: a possible regulator of retinal angiogenesis. Exp Cell Res 2004;299:68-78.
11.
Shen W, Fruttiger M, Zhu L, et al: Conditional Müller cell ablation causes independent neuronal and vascular pathologies in a novel transgenic model. J Neurosci 2012;32:15715-15727.
12.
Eichler W, Yafai Y, Kuhrt H, et al: Hypoxia: modulation of endothelial cell proliferation by soluble factors released by retinal cells. Neuroreport 2001;12:4103-4108.
13.
Eichler W, Yafai Y, Wiedemann P, Reichenbach A: Angiogenesis-related factors derived from retinal glial (Müller) cells in hypoxia. Neuroreport 2004;15:1633-1637.
14.
Yafai Y, Lange J, Wiedemann P, Reichenbach A, Eichler W: Pigment epithelium-derived factor acts as an opponent of growth-stimulatory factors in retinal glial-endothelial cell interactions. Glia 2007;55:642-651.
15.
Yafai Y, Iandiev I, Lange J, Wiedemann P, Reichenbach A, Bringmann A, Eichler W: Müller glial cells inhibit proliferation of retinal vascular endothelial cells via TGF-β2 and Smad signalling. Submitted.
16.
Yafai Y, Iandiev I, Wiedemann P, Reichenbach A, Eichler W: Retinal endothelial angiogenic activity: effects of hypoxia and glial (Müller) cells. Microcirculation 2004;11:577-586.
17.
Yafai Y, Iandiev I, Lange J, et al: Basic fibroblast growth factor contributes to a shift in the angioregulatory activity of retinal glial (Müller) cells. PLoS One 2013;8:e68773.
18.
Crawford SE, Stellmach V, Murphy-Ullrich JE, et al: Thrombospondin-1 is a major activator of TGF-β1 in vivo. Cell 1998;93:1159-1170.
19.
Zamiri P, Masli S, Kitaichi N, Taylor AW, Streilein JW: Thrombospondin plays a vital role in the immune privilege of the eye. Invest Ophthalmol Vis Sci 2005;46:908-919.
20.
Yu K, Ge J, Summers JB, et al: TSP-1 secreted by bone marrow stromal cells contributes to retinal ganglion cell neurite outgrowth and survival. PLoS One 2008;3:e2470.
21.
Ng TF, Turpie B, Masli S: Thrombospondin-1-mediated regulation of microglia activation after retinal injury. Invest Ophthalmol Vis Sci 2009;50:5472-5478.
22.
Huang J, Zhou L, Wang H, et al: Distribution of thrombospondins and their neuronal receptor α2δ1 in the rat retina. Exp Eye Res 2013;111:36-49.
23.
Wu Z, Wang S, Sorenson CM, Sheibani N: Attenuation of retinal vascular development and neovascularization in transgenic mice over-expressing thrombospondin-1 in the lens. Dev Dyn 2006;235:1908-1920.
24.
Chen M, Copland DA, Zhao J, et al: Persistent inflammation subverts thrombospondin-1-induced regulation of retinal angiogenesis and is driven by CCR2 ligation. Am J Pathol 2012;180:235-245.
25.
Suzuma K, Takagi H, Otani A, Oh H, Honda Y: Expression of thrombospondin-1 in ischemia-induced retinal neovascularization. Am J Pathol 1999;154:343-354.
26.
Wang JY, Gu YS, Yan LP, Teng XD, Zhang XM: The effect of cilostazol on expression of thrombospondin-1 in diabetic retinopathy. Fen Zi Xi Bao Sheng Wu Xue Bao 2008;41:301-308.
27.
Xu L, Liu YM, Yao ZJ, et al: Generation of trans-arachidonic acid under nitrative stress is associated with upregulation of thrombospondin-1 in diabetic rats. Chin Med J (Engl) 2011;124:1885-1889.
28.
Weller M, Esser P, Bresgen M, Heimann K, Wiedemann P: Thrombospondin: a new attachment protein in preretinal traction membranes. Eur J Ophthalmol 1992;2:10-14.
29.
Hiscott P, Larkin G, Robey HL, Orr G, Grierson I: Thrombospondin as a component of the extracellular matrix of epiretinal membranes: comparisons with cellular fibronectin. Eye (Lond) 1992;6:566-569.
30.
Graham CE, Binz N, Shen WY, Constable IJ, Rakoczy EP: Laser photocoagulation: ocular research and therapy in diabetic retinopathy. Adv Exp Med Biol 2006;572:195-200.
31.
Binz N, Graham CE, Simpson K, et al: Long-term effect of therapeutic laser photocoagulation on gene expression in the eye. FASEB J 2006;20:383-385.
32.
Sun J, Hopkins BD, Tsujikawa K, et al: Thrombospondin-1 modulates VEGF-A-mediated Akt signaling and capillary survival in the developing retina. Am J Physiol Heart Circ Physiol 2009;296:H1344-H1351.
33.
Scheef EA, Sorenson CM, Sheibani N: Attenuation of proliferation and migration of retinal pericytes in the absence of thrombospondin-1. Am J Physiol Cell Physiol 2009;296:C724-C734.
34.
Nork TM, Wallow IHL, Sramek SJ, Anderson G: Müller's cell involvement in proliferative diabetic retinopathy. Arch Ophthalmol 1987;105:1424-1429.
35.
Bringmann A, Pannicke T, Grosche J, et al: Müller cells in the healthy and diseased retina. Prog Retin Eye Res 2006;25:397-424.
36.
Limb GA, Salt TE, Munro PM, Moss SE, Khaw PT: In vitro characterization of a spontaneously immortalized human Müller cell line (MIO-M1). Invest Ophthalmol Vis Sci 2002;43:864-869.
37.
Bringmann A, Iandiev I, Pannicke T, et al: Cellular signaling and factors involved in Müller cell gliosis: neuroprotective and detrimental effects. Prog Retin Eye Res 2009;28:423-451.
38.
Stone J, Itin A, Alon T, et al: Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 1995;15:4738-4747.
39.
Hecquet C, Lefevre G, Valtink M, Engelmann K, Mascarelli F: Activation and role of MAP kinase-dependent pathways in retinal pigment epithelial cells: ERK and RPE cell proliferation. Invest Ophthalmol Vis Sci 2002;43:3091-3098.
40.
Lange CA, Bainbridge JW: Oxygen sensing in retinal health and disease. Ophthalmologica 2012;227:115-131.
41.
Sennlaub F, Courtois Y, Goureau O: Inducible nitric oxide synthase mediates the change from retinal to vitreal neovascularization in ischemic retinopathy. J Clin Invest 2001;107:717-725.
42.
Lundkvist A, Reichenbach A, Betsholtz C, Carmeliet P, Wolburg H, Pekny M: Under stress, the absence of intermediate filaments from Müller cells in the retina has structural and functional consequences. J Cell Sci 2004;117:3481-3488.
43.
Joyal JS, Sitaras N, Binet F, et al: Ischemic neurons prevent vascular regeneration of neural tissue by secreting semaphorin 3A. Blood 2011;117:6024-6035.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.